NCT02499783View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

August 17, 2015

Primary Completion Date

May 19, 2017

Study Completion Date

December 15, 2017

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

adalimumab

subcutaneous injections of adalimumab

OTHER

placebo

subcutaneous injections of placebo

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY